Gale, Christopher-Michael
Beth Israel Deaconess Medical Center · Harvard University · Massachusetts General Hospital · Dana-Farber Cancer Institute
2 papers on CoChat
Most cited papers
- Verified
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 4,496
- Verified
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 730
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free